Deep-learning CT response score stratifies outcomes in lung-cancer immunotherapy cohorts
A deep-learning radiomic pipeline generated a pretreatment CT response score (CTRS) for advanced non-small-cell lung cancer treated with PD-(L)1 checkpoint inhibitors. In an independent real-world test cohort, high-response-score first-line ICI-monotherapy patients had longer progression-free and overall survival after adjustment for baseline covariates including PD-L1 (adjusted HR 0.46 and 0.50). In a secondary analysis of 54 participants from a prospective sasanlimab trial, the score was associated with overall survival (adjusted HR 0.33) but not progression-free survival.
Technology: Three-dimensional hierarchical convolutional neural network feature extractor combined with a Cox survival model (CT response score, CTRS)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In an independent real-world test cohort, high-response-score first-line ICI-monotherapy patients had longer progression-free and overall survival after adjustment for baseline covariates including PD-L1 (adjusted HR 0.46 and 0.50).
- Still unknown: The real-world data were retrospective. Association of the score with survival among treated patients does not establish that the score predicts differential treatment benefit versus an untreated or alternative-treatment control. Clinical-trial analysis was secondary and small (n=54): PFS association was not significant, while OS association was significant. Authors say larger prospective studies are needed; no improved-care or deployment outcome is shown.
- AI role: The model learned image features from pretreatment CT/PET-CT scans and combined them with a Cox survival model to produce an imaging-only response score. Researchers evaluated the score in a held-out real-world cohort and in a secondary analysis of a prospective clinical-trial cohort; it stratified PFS/OS in the first and OS in the latter.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11658027/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 19 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.